See more : Wiener Privatbank SE (WPB.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Jiangsu gdk Biotechnology Co., Ltd. (688670.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jiangsu gdk Biotechnology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- SVB Financial Group (SIVBP) Income Statement Analysis – Financial Results
- Ten Allied Co.,Ltd. (8207.T) Income Statement Analysis – Financial Results
- Tidal Trust II – Defiance S&P 500 Enhanced Options & 0DTE Income ETF (WDTE) Income Statement Analysis – Financial Results
- JS Global Lifestyle Company Limited (JGLCF) Income Statement Analysis – Financial Results
- Northern Data AG (NB2.F) Income Statement Analysis – Financial Results
Jiangsu gdk Biotechnology Co., Ltd. (688670.SS)
About Jiangsu gdk Biotechnology Co., Ltd.
Jiangsu gdk Biotechnology Co., Ltd., a biological company, engages in the scientific research, production, operation, and service of human vaccines. The company offers quadrivalent influenza virus split and lyophilized human rabies vaccines. Its product pipeline has coverage for the prevention of principal infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. The company was founded in 2008 and is based in Taizhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 134.59M | 318.49M | 392.27M | 589.10M | 67.15M | 0.00 | 0.00 |
| Cost of Revenue | 29.86M | 50.59M | 57.18M | 73.67M | 10.49M | 21.07M | 0.00 |
| Gross Profit | 104.73M | 267.90M | 335.09M | 515.43M | 56.66M | -21.07M | 0.00 |
| Gross Profit Ratio | 77.81% | 84.12% | 85.42% | 87.49% | 84.37% | 0.00% | 0.00% |
| Research & Development | 15.47M | 32.41M | 35.26M | 28.53M | 23.75M | 12.08M | 18.32M |
| General & Administrative | 13.49M | 12.99M | 12.57M | 24.16M | 7.61M | 7.31M | 7.65M |
| Selling & Marketing | 68.45M | 107.49M | 116.27M | 209.13M | 25.97M | 0.00 | 0.00 |
| SG&A | 81.94M | 120.49M | 128.84M | 233.29M | 33.58M | 7.31M | 7.65M |
| Other Expenses | 82.01M | 36.82M | 27.92M | 16.17M | 24.44M | -7.37K | 25.39K |
| Operating Expenses | 179.42M | 189.72M | 192.02M | 277.99M | 81.78M | 38.78M | 44.24M |
| Cost & Expenses | 209.28M | 240.31M | 249.19M | 351.66M | 92.27M | 38.78M | 44.24M |
| Interest Income | 1.90M | 1.66M | 2.75M | 265.96K | 6.87K | 4.46K | 4.54K |
| Interest Expense | 1.90M | 1.28M | 9.85M | 9.64M | 2.97M | 2.66M | 3.24M |
| Depreciation & Amortization | 31.25M | 31.14M | 29.21M | 25.81M | 23.30M | 21.07M | 18.62M |
| EBITDA | -53.38M | 79.45M | 121.93M | 246.39M | -4.98M | -19.66M | -25.26M |
| EBITDA Ratio | -39.66% | 39.22% | 45.60% | 44.66% | -2.75% | 0.00% | 0.00% |
| Operating Income | -81.67M | 95.16M | 150.79M | 211.74M | -25.12M | -41.36M | -47.33M |
| Operating Income Ratio | -60.68% | 29.88% | 38.44% | 35.94% | -37.41% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.90M | -529.60K | 34.35K | -812.93K | -6.13M | -7.37K | 25.39K |
| Income Before Tax | -86.57M | 48.41M | 84.00M | 210.93M | -31.25M | -41.36M | -47.30M |
| Income Before Tax Ratio | -64.32% | 15.20% | 21.41% | 35.81% | -46.53% | 0.00% | 0.00% |
| Income Tax Expense | -15.58M | 6.86M | 1.54M | 55.95M | -12.21M | -13.35M | -14.64M |
| Net Income | -70.99M | 41.54M | 82.46M | 154.98M | -19.04M | -28.01M | -32.66M |
| Net Income Ratio | -52.75% | 13.04% | 21.02% | 26.31% | -28.35% | 0.00% | 0.00% |
| EPS | -0.58 | 0.34 | 0.67 | 1.26 | -0.15 | -0.40 | -0.46 |
| EPS Diluted | -0.58 | 0.34 | 0.67 | 1.26 | -0.15 | -0.40 | -0.65 |
| Weighted Avg Shares Out | 122.40M | 123.20M | 123.20M | 123.20M | 123.20M | 70.03M | 70.35M |
| Weighted Avg Shares Out (Dil) | 122.40M | 123.20M | 123.20M | 123.20M | 123.20M | 70.03M | 50.25M |
Source: https://incomestatements.info
Category: Stock Reports